Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.58 |
| ▸ | AXL | P30530 | 7/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168001 | 0.90 | AXL (0.54) | METAXLFLT3KDR | |
| SCHEMBL371859 | 0.89 | AXL (0.65) | METAXLFLT3KDR | |
| SCHEMBL29693573 | 0.89 | AXL (0.65) | METAXLFLT3KDR | |
| SCHEMBL3542937 | 0.87 | MET (0.56) | METAXLFLT3KDR | |
| SCHEMBL3542938 | 0.87 | MET (0.56) | METAXLFLT3KDR | |
| SCHEMBL5411428 | 0.86 | AXL (0.60) | METAXLFLT3KDR | |
| SCHEMBL2744533 | 0.84 | MET (0.60) | METAXLFLT3KDR | |
| SCHEMBL15966757 | 0.82 | MET (0.75) | METAXLFLT3KDR | |
| SCHEMBL5571100 | 0.81 | MET (0.57) | METAXLFLT3KDR | |
| SCHEMBL5049534 | 0.81 | MET (0.89) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769976-B1 | HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF | BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| EP-2769976-A1 | HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007033196-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | HDAC5, HDAC1, HDAC7 | MET 1782/4885AXL 2018/4885FLT3 304/4885 |
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | MET 1/4885AXL 562/4885FLT3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.